TY - JOUR
T1 - European guidelines on managing adverse effects of medication for ADHD
AU - Graham, J
AU - Banaschewski, T
AU - Buitelaar, J
AU - Coghill, D
AU - Danckaerts, M
AU - Dittmann, R W
AU - Döpfner, M
AU - Hamilton, Andrew Raymond
AU - Hollis, C
AU - Holtmann, M
AU - Hulpke-Wette, M
AU - Lecendreux, M
AU - Rosenthal, E
AU - Rothenberger, A
AU - Santosh, P
AU - Sergeant, J
AU - Simonoff, E
AU - Sonuga-Barke, E
AU - Wong, I C K
AU - Zuddas, A
AU - Steinhausen, H-C
AU - Taylor, John E.
AU - European Guidelines Group
PY - 2011/1/1
Y1 - 2011/1/1
N2 - The safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed medications. These relate to both relatively minor adverse effects and extremely serious issues such as sudden cardiac death and suicidality. A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has therefore reviewed the literature, recruited renowned clinical subspecialists and consulted as a group to examine these concerns. Some of the effects examined appeared to be minimal in impact or difficult to distinguish from risk to untreated populations. However, several areas require further study to allow a more precise understanding of these risks.
AB - The safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed medications. These relate to both relatively minor adverse effects and extremely serious issues such as sudden cardiac death and suicidality. A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has therefore reviewed the literature, recruited renowned clinical subspecialists and consulted as a group to examine these concerns. Some of the effects examined appeared to be minimal in impact or difficult to distinguish from risk to untreated populations. However, several areas require further study to allow a more precise understanding of these risks.
KW - Adrenergic Uptake Inhibitors
KW - Attention Deficit Disorder with Hyperactivity
KW - Cardiovascular Diseases
KW - Central Nervous System Stimulants
KW - Child
KW - Clinical Trials as Topic
KW - Drug Administration Schedule
KW - Drug Dosage Calculations
KW - Drug Tolerance
KW - Drug Utilization Review
KW - Europe
KW - Humans
KW - Monitoring, Physiologic
KW - Propylamines
KW - Risk Assessment
KW - Substance-Related Disorders
KW - Suicide, Attempted
U2 - 10.1007/s00787-010-0140-6
DO - 10.1007/s00787-010-0140-6
M3 - Journal article
SN - 1018-8827
VL - 20
SP - 17
EP - 37
JO - European Child & Adolescent Psychiatry
JF - European Child & Adolescent Psychiatry
ER -